The National Academies Press

Currently Skimming:

Appendix A: Statement of Task
Pages 103-104

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.

From page 103... ... Participants will be invited to discuss topics that may include • An overview of the limitations of current preclinical models for immunotherapies and efforts to identify predictive, prognostic, or pharmacodynamic biomarkers for improved models and therapies; • Challenges in clinical trial design and implementation, such as strategies to combine the best standard of care therapies with tar geted immunotherapies or combining multiple immune therapeutic agents, expedient patient identification for inclusion in studies, modification and use of genetically altered cells, and mitigation of adverse effects for patients; • Opportunities for greater collaboration and information exchange, including the collection, curation, distribution, and analysis of appropriate patient samples for continuing laboratory studies; • Opportunities for greater collaboration and information exchange between bio and pharmaceutical companies, especially by expansion of precompetitive space; 103 Read the entire page →
From page 104... ... 104 POLICY ISSUES FOR CANCER IMMUNOTHERAPY • Gaps in policy surrounding the development, regulation, and clini cal implementation of cell-based and gene-based immunotherapies; and • Strategies for scaling up production of novel Food and Drug A dministration–approved immunotherapies to facilitate broad patient access. The committee will develop the agenda for the workshop sessions, select and invite speakers and discussants, and moderate the discussions. An individually authored workshop summary of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines. Read the entire page →

From page 103...

... Participants will be invited to discuss topics that may include • An overview of the limitations of current preclinical models for immunotherapies and efforts to identify predictive, prognostic, or pharmacodynamic biomarkers for improved models and therapies; • Challenges in clinical trial design and implementation, such as strategies to combine the best standard of care therapies with tar geted immunotherapies or combining multiple immune therapeutic agents, expedient patient identification for inclusion in studies, modification and use of genetically altered cells, and mitigation of adverse effects for patients; • Opportunities for greater collaboration and information exchange, including the collection, curation, distribution, and analysis of appropriate patient samples for continuing laboratory studies; • Opportunities for greater collaboration and information exchange between bio and pharmaceutical companies, especially by expansion of precompetitive space; 103

Read the entire page →

From page 104...

... 104 POLICY ISSUES FOR CANCER IMMUNOTHERAPY • Gaps in policy surrounding the development, regulation, and clini cal implementation of cell-based and gene-based immunotherapies; and • Strategies for scaling up production of novel Food and Drug A dministration–approved immunotherapies to facilitate broad patient access. The committee will develop the agenda for the workshop sessions, select and invite speakers and discussants, and moderate the discussions. An individually authored workshop summary of the presentations and discussions at the workshop will be prepared by a designated rapporteur in accordance with institutional guidelines.

Read the entire page →

← Previous Chapter Skim

Next Chapter Skim →

This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More information on Chapter Skim is available.

Appendix A: Statement of Task Pages 103-104

Appendix A: Statement of Task
Pages 103-104